Published in Arch Dermatol on May 01, 1978
Mutational status of naevus-associated melanomas. Br J Dermatol (2015) 2.68
Self screening for risk of melanoma: validity of self mole counting by patients in a single general practice. BMJ (1995) 1.81
The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects. J Am Acad Dermatol (2012) 1.79
Excess benign melanocytic naevi after chemotherapy for malignancy in childhood. BMJ (1989) 1.73
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer (1996) 1.71
Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am J Hum Genet (1986) 1.39
Tumour spectrum in the FAMMM syndrome. Br J Cancer (1981) 1.24
Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases. Am J Pathol (1979) 1.18
Primary choroidal and cutaneous melanomas, bilateral choroidal melanomas, and familial occurrence of melanomas. Br J Ophthalmol (1982) 1.08
Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet (1993) 1.08
Proposed alternative terminology and subclassification of so called "dysplastic naevi". J Clin Pathol (1986) 1.07
Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. Int J Cancer (2009) 1.04
The dysplastic naevus. J Clin Pathol (1997) 1.02
Mutation testing in melanoma families: INK4A, CDK4 and INK4D. Br J Cancer (1999) 1.01
Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome Ip36. Am J Hum Genet (1990) 1.00
Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma. Br J Cancer (1980) 0.99
Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev (2013) 0.98
Atypical mole syndrome and dysplastic nevi: identification of populations at risk for developing melanoma - review article. Clinics (Sao Paulo) (2011) 0.97
The dysplastic nevus: from historical perspective to management in the modern era: part II. Molecular aspects and clinical management. J Am Acad Dermatol (2012) 0.96
Frequency of moles in a defined population. J Epidemiol Community Health (1985) 0.95
Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn (2002) 0.92
NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi. PLoS One (2013) 0.90
Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol (2005) 0.90
Moderate- to low-risk variant alleles of cutaneous malignancies and nevi: lessons from genome-wide association studies. Genome Med (2009) 0.88
Surgical prophylaxis of malignant melanoma. Ann Surg (1991) 0.88
Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am J Hum Genet (1993) 0.86
Phenotypic variation in the familial atypical multiple mole-melanoma syndrome (FAMMM). J Med Genet (1983) 0.86
From melanocytes to melanomas. Nat Rev Cancer (2016) 0.85
UV exposure modulates hemidesmosome plasticity, contributing to long-term pigmentation in human skin. J Pathol (2015) 0.84
Hereditary genodermatoses with cancer predisposition. Hematol Oncol Clin North Am (2010) 0.83
Melanoma risk factors and atypical moles. West J Med (1994) 0.83
Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol (1995) 0.82
Genetics of melanocytic nevi. Pigment Cell Melanoma Res (2015) 0.81
Epidemiologic clues to the cause of melanoma. West J Med (1979) 0.80
Genetic determinants of cutaneous melanoma predisposition. Semin Cutan Med Surg (2010) 0.80
On the clinical significance of cutaneous melanoma's precursors. Indian Dermatol Online J (2012) 0.79
Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol (2016) 0.78
The ultrastructure of dysplastic naevi: comparison with superficial spreading melanoma and common naevocellular naevi. Arch Dermatol Res (1990) 0.77
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
Analysis of interobserver reproducibility in grading histological patterns of dysplastic nevi. An Bras Dermatol (2013) 0.76
Correlation of clinical pigmentary characteristics with histopathologically-confirmed dysplastic nevi in nonfamilial melanoma patients. Studies of melanocytic nevi IX. Br J Cancer (1991) 0.76
Study of the histopathological types of cutaneous melanoma in Palmas-TO from 2001 to 2011. An Bras Dermatol (2015) 0.75
Grading melanocytic dysplasia in paraffin wax embedded tissue by the nucleic acid index. J Clin Pathol (2005) 0.75
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne) (2016) 0.75
Evidence for autosomal dominance and pleiotropy of the cutaneous malignant melanoma (CMM)/Dysplastic nevus (DN) gene. Am J Hum Genet (1987) 0.75
Pathology: dysplastic nevi. West J Med (1986) 0.75
Malignant melanoma in a black child: predisposing precursors and management. J Natl Med Assoc (2004) 0.75
Familial dysplastic naevus syndrome. J R Soc Med (1988) 0.75
Eleven Primary Melanomas, Colon Cancer, and Atypical Nevi in the Same Patient: A Case Report and Literature Review. Case Rep Dermatol Med (2016) 0.75
Amelanotic Melanoma in the Vicinity of Acquired Melanocytic Nevi and not Arising from Agminated Melanocytic Nevi: Masquerading as Pyogenic Granuloma. Indian J Dermatol (2016) 0.75
A linkage study between HLA and cutaneous malignant melanoma or precursor lesions or both. J Med Genet (1984) 0.75
Common Skin Cancers: How to diagnose and treat them. Can Fam Physician (1992) 0.75
[Dysplastic melanocytic nevus]. Pathologe (2015) 0.75
The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
THE CLINICAL EVALUATION OF AUREOMYCIN. J Clin Invest (1949) 3.60
A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol (1984) 3.21
Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med (1989) 3.03
The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67
Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA (1997) 2.65
Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med (1985) 2.54
Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36
Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med (1977) 2.20
Drinking and driving in the United States: the 1996 National Roadside Survey. Accid Anal Prev (1998) 2.11
Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer (1980) 2.04
The developmental biology of primary human malignant melanomas. Semin Oncol (1975) 1.92
Premarital sex, schoolgirl pregnancy, and school quality in rural Kenya. Stud Fam Plann (2001) 1.91
Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg (1983) 1.89
Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res (1985) 1.85
Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res (1975) 1.75
Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA (1978) 1.74
Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci U S A (1983) 1.72
Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68
The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65
The dysplastic nevus syndrome: our definition. Am J Dermatopathol (1982) 1.63
A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med (1996) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
The prenatal diagnosis of imperforate anus with rectourinary fistula: dilated fetal colon with enterolithiasis. J Pediatr Surg (1992) 1.54
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
The biologic forms of malignant melanoma. Hum Pathol (1986) 1.51
Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line. Proc Natl Acad Sci U S A (1991) 1.49
Primary malignant melanoma of the urinary bladder. Cancer (1976) 1.48
Melanoma and vitiligo: immunology's Grecian urn. Cancer Immunol Immunother (1996) 1.44
Cyclosporin use in the precolectomy chronic ulcerative colitis patient: a community experience and its relationship to prospective and controlled clinical trials. Pacific Northwest Gastroenterology Society. Am J Gastroenterol (1995) 1.43
Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43
Cesarean delivery in a patient with a transplanted heart. Anesthesiology (1989) 1.41
Role of arteriography in the selection of patients for carotid endarterectomy. Br J Surg (1998) 1.39
Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36
How well do physicians recognize melanoma and other problem lesions? J Am Acad Dermatol (1986) 1.34
Karyotypic evolution in human malignant melanoma. Cancer Genet Cytogenet (1986) 1.34
Malignant melanoma in renal-transplant recipients. Lancet (1981) 1.33
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res (1988) 1.32
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol (1986) 1.30
Bacillus Calmette-Guerin in the treatment of neoplastic disease. J Reticuloendothel Soc (1974) 1.29
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
A fine-structure study of the human epidermal melanosome complex and its acid phosphatase activity. J Ultrastruct Res (1968) 1.26
Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res (1986) 1.25
Mucosal infection of neonatal rhesus monkeys with cell-free SIV. AIDS Res Hum Retroviruses (1994) 1.25
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Protracted survival after resection of metastatic uveal melanoma. Cancer (2000) 1.21
Laparoscopic splenectomy: outcomes and lessons learned from over 200 cases. Surgery (2000) 1.20
Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases. Am J Pathol (1979) 1.18
Progressive arterial occlusive disease (Köhlmeier-Degos). A frequently fatal cutaneosystemic disorder. N Engl J Med (1967) 1.17
Confrontation naming of environmental sounds. J Clin Exp Neuropsychol (2000) 1.15
Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet (1984) 1.15
Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res (1984) 1.14
Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer (1992) 1.14
Interleukin 10 production by human melanoma. Clin Cancer Res (1996) 1.12
Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet (1980) 1.12
Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol (1984) 1.11
Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. Eur J Immunol (1979) 1.10
Follow-up of atrial fibrillation: The initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J (1996) 1.10
Hyperaldosteronism and sudden cardiac death. Am J Cardiol (1996) 1.09
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother (1998) 1.09
Non-adaptive rejection of small tumour inocula as a model of immune surveillance. Nature (1976) 1.09
Pancreatic cancer in father and son. Lancet (1977) 1.09
Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet (1993) 1.08
Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res (1989) 1.07
A clinical histologic, and immunologic study of a case of metastatic malignant melanoma undergoing spontaneous remission. Cancer (1976) 1.06
Expression of DR antigens in freshly frozen human tumors. Hybridoma (1982) 1.05
Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases. Cancer (1975) 1.05
The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi. Semin Diagn Pathol (1993) 1.03
Possible involvement of the chromosome region 10q24----q26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet (1988) 1.03
Carotid body tumors in humans: genetics and epidemiology. J Natl Cancer Inst (1982) 1.02
Second primary neoplasms following ovarian cancer. J Natl Cancer Inst (1978) 1.01
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res (1994) 1.01
Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol (1990) 1.01
Augmentation of the human immune response by cyclophosphamide. Cancer Res (1982) 1.00
Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res (1987) 1.00
Crystal structure of a cross-reaction complex between Fab F9.13.7 and guinea fowl lysozyme. J Biol Chem (1995) 0.99
Sequential in vitro reactivity of lymphocytes from melanoma patients receiving immunotherapy compared with the reactivity of lymphocytes from healthy donors. Int J Cancer (1975) 0.99
BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res (1997) 0.99
Dysplastic naevi and cutaneous melanoma risk. Lancet (1983) 0.99
Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest (1988) 0.98
Relationship between patients' early recognition of melanoma and depth of invasion. Cancer (1982) 0.98
Dysplastic nevi on the scalp of prepubertal children from melanoma-prone families. J Pediatr (1983) 0.98
The clinical diagnosis of malignant melanoma. Semin Oncol (1975) 0.98
Disorders of the panniculus adiposus. Hum Pathol (1973) 0.98
Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest (1997) 0.97
A t(1;19) chromosome translocation in three cases of human malignant melanoma. Cancer Res (1986) 0.97
Malignant melanoma simulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol (1990) 0.97
Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol (1990) 0.97
Molecular phylogeny and biogeography of the marine shrimp Penaeus. Mol Phylogenet Evol (1998) 0.96
Theory and application of early systemic therapy. Semin Oncol (1991) 0.96
Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol (1997) 0.96
Production and characterization of monoclonal antibodies against human malignant melanoma. Cancer Invest (1983) 0.96